Wiedemann Herbert P, Arroliga Alejandro C, Komara John J
Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A-90, Cleveland, OH 44195, USA.
Respir Care Clin N Am. 2003 Dec;9(4):419-35. doi: 10.1016/s1078-5337(03)00033-9.
The increased understanding of the pathophysiology of ALI that has been achieved over the last decade has led to several new pharmacologic approaches for the prevention and management of ALI and ARDS. Based on in vitro information and animal model data, many of these strategies seem quite compelling. Nevertheless, to date, no specific pharmacologic approach for the prevention or treatment of ARDS has been conclusively validated in clinical trials. Active basic and clinical research continues, and it is hoped that these investigations will lead to new therapies that can be applied by the clinician to improve clinical outcomes for patients who have ALI and ARDS.
在过去十年中，人们对急性肺损伤（ALI）病理生理学的认识不断加深，这催生了几种预防和治疗ALI及急性呼吸窘迫综合征（ARDS）的新药物疗法。基于体外研究信息和动物模型数据，其中许多策略似乎颇具吸引力。然而，迄今为止，尚无任何预防或治疗ARDS的特定药物疗法在临床试验中得到最终验证。基础和临床研究仍在积极进行，人们希望这些研究能够带来新的治疗方法，供临床医生应用，以改善ALI和ARDS患者的临床结局。
